BioCentury | Nov 26, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Macaque studies identified a mAb targeting a hinge region in EDIII that could help treat Zika infection. Crystallographic analysis of a mAb isolated from a patient whose serum had high neutralizing activity...
BioCentury | Feb 8, 2017
Distillery Techniques

Drug platforms

TECHNOLOGY: Structural analyses Structural studies of patient-derived mAbs bound to domains of Zika virus Env could help guide the development of therapeutic mAbs to treat Zika infection. Isolation and cloning of B cells from a...
BioCentury | Aug 11, 2014
Financial News

Enumeral Biomedical completes private placement of units

Enumeral Biomedical Holdings Inc. (OTCQB:ENUM), Cambridge, Mass. Business: Cancer Date completed: 2014-08-04 Type: Private placement of units Raised: $21.5 million Units: 21.5 million Price: $1 (unit) Shares after offering: 50.1 million Placement agent: EDI Financial...
BioCentury | Aug 5, 2014
Financial News

Enumeral raises $21.5M, reverse-merges

Enumeral Biomedical Holdings Inc. (OTCQB:ENUM) reverse-merged with shell company Cerulean Group Inc. and began trading on the OTCQB. The immunotherapy company also raised $21.5 million through the sale of 21.5 million units at $1 in...
BioCentury | Jun 30, 2014
Company News

Edimer, InformedDNA deal

Informed Medical Decisions (InformedDNA) developed a genetic counseling program for patients and families affected by X-linked hypohydrotic ectodermal dysplasia (XLHED) in which InformedDNA may identify individuals that may benefit from treatment with Edimer’s EDI200 . As...
BioCentury | Oct 14, 2013
Financial News

Neurotrope completes private placement of convertible preferred stock

Neurotrope Inc. (OTCQB: NTRP), Plantation, Fla. Business: Neurology Date completed: 10/9/13 Type: Private placement of convertible preferred stock Raised: $1.1 million Shares: 1.1 million Price: $1 Placement agents: EDI Financial; Gottbetter Capital Markets Shares outstanding...
BioCentury | Oct 14, 2013
Clinical News

Fc-EDA1: Phase II started

Edimer began an open-label, dose-escalation, international Phase II trial to evaluate 3 and 10 mg/kg EDI200 in about 6 male newborns with XLHED. Dosing will begin between days 2 and 14 after birth with each...
BioCentury | Jul 31, 2013
Financial News

Edimer secures $18M in series B

Edimer Pharmaceuticals Inc. (Cambridge, Mass.) secured $18 million in a tranched series B round led by new investor New Enterprise Associates (NEA). New investor Sanofi-Genzyme BioVentures also participated, along with existing investors Third Rock Ventures...
BioCentury | Aug 27, 2012
Emerging Company Profile

Edimer: Gland idea

Unlike enzyme replacement therapies that are taken chronically for life, Edimer Pharmaceuticals Inc. hopes a single course of its EDI200 given either before or soon after birth will permanently correct a rare developmental disorder. The...
BioCentury | Jun 18, 2012
Clinical News

Fc-EDA1 regulatory update

FDA granted Fast Track designation for Edimer's EDI200 to treat X-linked hypohidrotic ectodermal dysplasia (XLHED). EDI200 is a recombinant protein comprised of the Fc domain of human IgG1 and tumor necrosis factor (TNF) domain of...
Items per page:
1 - 10 of 14